$HAE News

Haemonetics Consensus Price Target Raised 24.88% to $145.63

Haemonetics (HAE): Buy, Sell, or Hold Post Q2 Earnings?

Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System

Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures

Barrington Research Maintains Outperform on Haemonetics, Raises Price Target to $140

Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

Haemonetics: CSL Plasma Improves The Outlook, Not The Entry Point (Rating Downgrade)

Haemonetics (HAE) Jumped, What Is Behind The Move?

Haemonetics Soars 12% on CSL Update: Plasma Giant to Roll Out NexSys Across U.S. Centers

BTIG Maintains Buy on Haemonetics, Raises Price Target to $130

Haemonetics Stock Surges as Plasma Deal Opens Door to More Revenue

Haemonetics Stock Hits 52-Week High - Here's Why

PAHC vs. HAE: Which Stock Is the Better Value Option?

Haemonetics Q1 2027 Earnings Call Transcript

Haemonetics Sets Date for Publishing Second Quarter Fiscal Year 2027 Results: November 5, 2026

Haemonetics (NYSE:HAE): A Quality Investing Candidate Built on Durable Fundamentals

Haemonetics (HAE) Could Be 66% Undervalued After Margin Expansion Focus

Citigroup Upgrades Haemonetics to Buy from Neutral

Citigroup Upgrades Haemonetics to Buy, Raises Price Target to $123

Raymond James Maintains Outperform on Haemonetics, Raises Price Target to $125